Smith & Nephew 

€13.65
415
+€0.01+0.07% 今天

統計

當日最高
13.65
當日最低
13.65
52週最高
-
52週最低
-
成交量
0
平均成交量
-
市值
11.94B
市盈率
42.63
股息收益率
2.55%
股息
0.35

即將到來

股息

2.55%股息收益率
10年增長
4.64%
5年增長率
1%
3年增長率
2.97%
1年增長率
-2.18%

收益

1Aug確認
Q4 2022
Q1 2023
Q2 2023
Q3 2023
Q4 2023
Q1 2024
Q2 2024
0
16.07
32.13
48.2
預期每股收益
0.3928
實際每股收益
0.376

人們還關注

此列表基於在 Stock Events 上關注 NPW1.F 的人的關注列表。這不是投資建議。

競爭者

這個列表是基於最近市場事件的分析。這不是投資建議。

關於

Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom and internationally. It operates through three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products. It also provides sports medicine joint repair products comprise instruments, technologies, and implants to perform minimally invasive surgery, as well as treating soft tissue injuries and degenerative conditions of the shoulder, knee, hip, and small joints. In addition, the company offers arthroscopic enabling technologies comprising fluid management equipment for surgical access, high-definition cameras, digital image capture, scopes, light sources, and monitors to assist with visualization inside the joints, radio frequency, electromechanical and mechanical tissue resection devices, and hand instruments for removing damaged tissue; and ear, nose, and throat solutions. Further, it provides advanced wound care products for the treatment and prevention of acute and chronic wounds, which comprise leg wounds, diabetic and pressure ulcers, burns, and post-operative wounds; advanced wound bioactives, such as biologics and other bioactive technologies for debridement and dermal repair/regeneration, and regenerative medicine products, including skin, bone graft, and articular cartilage substitutes; and advanced wound devices, such as traditional and single-use negative pressure wound therapy, and hydrosurgery systems. The company serves the healthcare providers. Smith & Nephew plc was founded in 1856 and is headquartered in Watford, the United Kingdom.
Show more...
首席執行官
Dr. Deepak S. Nath Ph.D.
員工
18000
國家
GB
ISIN
GB0009223206
WKN
000502816

上市公司